Stride Inc header image

Stride Inc

LRN

Equity

ISIN null / Valor 58406765

New York Stock Exchange, Inc (2025-11-21)
USD 65.57-0.29%

Stride Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Stride, Inc., formerly known as K12 Inc., is an education technology company that has broadened its scope beyond its initial focus on K-12 online education. Since its rebranding in December 2020, the company has expanded its offerings to include diverse educational services and products for learners at various stages of life, from kindergarten through to adulthood. Stride, Inc. provides online and blended learning solutions, encompassing curriculum and technology platforms for students, schools, and enterprises. The company's evolution reflects a strategic shift towards serving a wider audience, aiming to equip individuals with the skills and knowledge necessary for career advancement and professional development. Trading on the NYSE under the symbol LRN, Stride, Inc. has positioned itself as a key player in the evolving landscape of education technology, catering to the needs of a broad demographic of learners across the United States.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (21.11.2025):

Stride Inc. — fourth quarter of fiscal 2025 (Q4 FY2025) and full fiscal 2025 results: Stride reported a record fiscal year with full-year revenue of $2,405.3 million (up 17.9% vs FY2024) and net income of $287.9 million (up 41.0%). Q4 FY2025 revenue was $653.6 million (up 22.4% YoY) while Q4 net income was $51.3 million (down 18.3% YoY). Adjusted measures were notably stronger: FY25 adjusted EBITDA of $571.0 million (up 46.1%) and adjusted EPS of $8.10 (up 47.5%). The company recorded a $59.5 million one-time impairment charge in Q4 related to its Galvanize business (excluded from adjusted metrics). Cash and marketable securities totaled $1,011.4 million as of June 30, 2025, and enrollments increased roughly 20% year over year.

Top-line growth

Full-year revenue of $2,405.3M, +17.9% vs FY2024. Q4 revenue $653.6M, +22.4% YoY. Segment detail — Q4 General Education: $394.1M (+13.6%); Q4 Career Learning total: $259.5M (+38.7%), with Career Learning middle–high school $240.5M (+43.8%). Adult learning declined modestly.

Profitability and adjusted performance

FY25 income from operations $360.1M (+44.3%) and net income $287.9M (+41.0%). FY25 adjusted operating income $466.2M (+58.6%) and adjusted EBITDA $571.0M (+46.1%); adjusted EPS $8.10 (+47.5%). These non‑GAAP measures exclude certain items per the company’s reconciliation.

Q4 profit dynamics

Q4 GAAP income from operations $56.9M (down 22.8% YoY) and Q4 net income $51.3M (down 18.3%). On an adjusted basis Q4 operating income was $130.6M (+48.5%) and adjusted EBITDA $158.4M (+41.3%); adjusted EPS in Q4 was $2.29 (+36.3%). The difference between GAAP and adjusted Q4 results reflects the $59.5M Galvanize impairment and other adjustments.

Enrollments and revenue per enrollment

Average full-year enrollments 234.0K, +20.4% vs FY24; Q4 average enrollments 235.3K, +21.7% YoY. Career Learning enrollments ~96.3K for the year (+32.5%) and ~97.0K in Q4 (+33.2%). Q4 revenue per enrollment $2,630 (+2.4% YoY); full‑year RPE $9,677 (+0.6%). Career Learning RPE rose ~8.1% in Q4.

Cash position and capital allocation

Cash and cash equivalents plus marketable securities totaled $1,011.4M at June 30, 2025 (vs $714.2M a year earlier). Capital expenditures for FY25 were $60.0M, including $36.4M capitalized software development and $21.8M capitalized curriculum development.

One-time impairment

The company recorded $59.5M of one-time charges in Q4 related to an impairment of the Galvanize business. Those charges are excluded from adjusted operating income, adjusted EBITDA and adjusted EPS reported by the company.

Outlook / momentum

Management states demand trends support continued momentum into fiscal 2026; a conference call and webcast were scheduled to discuss Q4 and FY25 results. The release did not provide formal FY26 financial guidance in the summarized report.

Summarized from source with an LLMView Source

Key figures

-36.6%1Y
82.7%3Y
175%5Y

Performance

88.6%1Y
61.2%3Y
57.3%5Y

Volatility

Market cap

2876 M

Market cap (USD)

Daily traded volume (Shares)

1,873,053

Daily traded volume (Shares)

1 day high/low

107.25 / 104.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Edwards Lifesciences Corp
Edwards Lifesciences Corp Edwards Lifesciences Corp Valor: 1065343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.24%USD 85.13
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%USD 101.12
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 13.91
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%SEK 260.90
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.18%SEK 342.20